Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Equity Average: 2020-2025

Historic Equity Average for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $284.7 million.

  • GeneDx Holdings' Equity Average rose 42.87% to $284.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $284.7 million, marking a year-over-year increase of 42.87%. This contributed to the annual value of $236.6 million for FY2024, which is 1.76% down from last year.
  • GeneDx Holdings' Equity Average amounted to $284.7 million in Q3 2025, which was up 6.52% from $267.3 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Equity Average peaked at $599.3 million during Q3 2022, and registered a low of -$544.2 million during Q2 2021.
  • Over the past 3 years, GeneDx Holdings' median Equity Average value was $251.3 million (recorded in 2025), while the average stood at $251.4 million.
  • In the last 5 years, GeneDx Holdings' Equity Average soared by 783.01% in 2022 and then slumped by 54.08% in 2023.
  • Over the past 5 years, GeneDx Holdings' Equity Average (Quarterly) stood at $389.6 million in 2021, then grew by 4.60% to $407.5 million in 2022, then plummeted by 40.83% to $241.1 million in 2023, then declined by 6.74% to $224.9 million in 2024, then soared by 42.87% to $284.7 million in 2025.
  • Its Equity Average stands at $284.7 million for Q3 2025, versus $267.3 million for Q2 2025 and $251.3 million for Q1 2025.